Study reveals how SARS-CoV-2 rewires human proteins for replication
A team of researchers has analysed how SARS-CoV-2 hijacks the proteins in its host cells to aid replication and infect nearby cells.
List view / Grid view
News
Therapies targeting AhRs and IDO1 could combat COVID-19, paper says
Researchers have hypothesised that treatments targeting the downregulation of AhRs and IDO1 genes could reduce severity of COVID-19 infection.
New muscular dystrophy treatment shows promise in pre-clinical trials
A group of researchers has used locked nucleic acid gapmer antisense oligonucleotides to treat facioscapulohumeral muscular dystrophy in cells and mice.
Six molecular targets for COVID-19 identified by researchers
A study of blood samples from COVID-19 patients has allowed a team to reveal six molecular targets that could be used to develop treatments for the virus.
X-rays reveal structure of SARS-CoV-2 protease at room temperature
Researchers grew large crystals and used an X-ray machine with a less intense beam to elucidate the structure of the SARS-CoV-2 main protease at room temperature.
Four compounds discovered in starfish show efficacy against cancer cells
Scientists have revealed that four molecules found in the Ceramaster patagonicus starfish show potency against cancer in cell lines.
Three molecules show promise as epilepsy treatments in pre-clinical trials
Researchers have synthesised three oligonucleotide inhibitor molecules which stopped seizures in mouse models, making them potential epilepsy drugs.
Study identifies 68 genes associated with risk of severe COVID-19
A study has revealed 68 protein-coding genes associated with risk of severe COVID-19, nine of which are targeted by drugs currently in clinical trials.
Targeting innate immunity with Transcreener® Assays
Over the past year, BellBrook Labs has leveraged its Transcreener HTS Assay technology to build enabling products and services focusing on innate immunity targets.
Promising COVID-19 drug candidate identified by virtual screening
After virtually screening 640 existing drug compounds, researchers have revealed that PC786 potently targets several SARS-CoV-2 receptors, making it a candidate to fight COVID-19.
Antisense oligonucleotide treatment cures Parkinson’s disease in mice
By administering a one-time PTB antisense oligonucleotide therapy to mice, researchers observed an increase in neurons and elimination of Parkinson's from the models.
Over 718 drugs in pipeline as potential COVID-19 treatments, says report
New research has found that of the 718 pipeline drugs associated with COVID-19, 70 percent are currently in the discovery or pre-clinical stages.
PL8177 shows success as COVID-19 therapy in pre-clinical trials
The drug candidate PL8177 reduced inflammation, protected lung tissue and reduced lung fibrosis in pre-clinical models with symptoms of COVID-19.
Novel compound could treat type 2 diabetes without common side effects
Two molecules combined into a new substance to treat type 2 diabetes lowered blood sugar in shrew models without causing nausea, vomiting and weight loss.
CD47 blockade could work as immunotherapy across multiple diseases
Researchers have demonstrated that blocking CD47-mediated signalling in mice can enhance the speed of pathogen clearance, presenting a new potential form of immunotherapy.